VISEN Pharmaceuticals
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Jing'an District 场 1788号1788 南京西路 1701室,...Website
www.visenpharma.comRevenue
$100.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About VISEN Pharmaceuticals
VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on endocrine-related therapies. The company aims to provide first-in-class and best-in-class products and treatment solutions for endocrine diseases, prioritizing patient needs. Their product pipeline includes treatments for growth hormone deficiency and hypoparathyroidism, utilizing their proprietary TransCon technology platform for improved patient compliance and outcomes. VISEN is committed to enhancing the treatment experience and efficacy for patients with endocrine disorders.Explore more
Popular SearchesVISEN PharmaceuticalsVISEN Pharma Co LtdSIC Code 28,283NAICS Code 32,325Show moreVISEN Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VISEN Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at VISEN Pharmaceuticals
Check out if VISEN Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once VISEN Pharmaceuticals has new funding data
Check if VISEN Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if VISEN Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when VISEN Pharmaceuticals launches new products
Earning: See what the market has to say on VISEN Pharmaceuticals recently announced quarterly report
VISEN Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
VISEN Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
VISEN Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about VISEN Pharmaceuticals.
VISEN Pharmaceuticals financials insights
Gather financial insights about VISEN Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$40M
2021
Series B
$150M
VISEN Pharmaceuticals Tech Stack
A closer look at the technologies used by VISEN Pharmaceuticals
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Person-Based
Person-Based
Funding
VISEN Pharmaceuticals News & Media
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
SHANGHAI, March 8, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Administration (NMPA). Lonapegsomatropin is the first once-weekly administrated growth hormone approved by both the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) for the treatmentOnce-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children with achondroplasia (ACH) aged 2 to 10 years. In the trial, patients dosed with TransCon CNP at the 100 μg CNP/kg/week showed significantly higher annualized growth velocity (AGV) than placebo (1.180 cm/year, P=0.018) at Week 52. The ACcomplisH China Phase 2 TriaDouble-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a...VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin
Currently the Only Long-Acting Growth Hormone Demonstrates Superior Annualized Height Velocity Compared to Daily hGH in Children with Growth Hormone Deficiency SHANGHAI, Nov. 17, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VISEN Pharmaceuticals
Sign Up For FreeTo access detailed company insights
VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on endocrine-related therapies. The company aims to provide first-in-class and best-in-class products and treatment solutions for endocrine diseases, prioritizing patient needs. Their product pipeline includes treatments for growth hormone deficiency and hypoparathyroidism, ut... Read More
